Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Lilly Neuroscience

    - PMLiVE

    Lilly and Indiana University collaborate to expand clinical trial access

    The five-year agreement includes a focus on R&D for Alzheimer’s disease

    - PMLiVE

    Novo Nordisk presents new findings on semaglutide in Alzheimer’s disease

    While the trials did not meet their primary endpoints, they highlighted important biomarker findings

    - PMLiVE

    Vandria announces positive phase 1 data for Alzheimer’s treatment

    Trial data showed that VNA-318 has the ability to penetrate the brain

    - PMLiVE

    Eisai submits new drug application for subcutaneous Leqembi in Japan

    LEQEMBI is a treatment for early Alzheimer’s disease

    - PMLiVE

    Biogen and Eisai receive MHRA approval for updated dosing of early Alzheimer’s treatment

    The MHRA approval for IV dosing comes following positive results from the global phase 3 trial

    - PMLiVE

    Lilly’s early Alzheimer’s disease treatment approved in the EU

    Marketing authorisation follows positive late-stage trial results

    - PMLiVE

    Breakthrough Alzheimer’s Therapies Drive Early Detection Rates While Exposing Deep Treatment Disparities

    Analysis from Komodo Health and Medscape Education shows cognitive screening up 10% and biomarker testing up 23%, yet significant disparities persist in detection for women and treatment access for Black...

    Medscape Education

    - PMLiVE

    Lilly launches global Alzheimer’s campaign with Julianne Moore

    The new ‘Brain Health Matters’ campaign urges the public to prioritise brain health

    - PMLiVE

    Eli Lilly’s Alzheimer’s drug Kisunla shows growing benefit in long-term study

    More than seven million people in the US are affected by the neurodegenerative disease

    - PMLiVE

    Eli Lilly’s Alzheimer’s disease drug donanemab recommended by CHMP

    Up to 6.9 million people in Europe are affected by the neurodegenerative disorder

    - PMLiVE

    AbbVie to expand neuroscience pipeline with $1.4bn Aliada Therapeutics acquisition

    The deal includes a candidate in phase 1 development for Alzheimer's disease

    - PMLiVE

    Eli Lilly shares positive results for modified titration of Alzheimer’s drug donanemab

    The neurodegenerative disorder accounts for up to 75% of the 982,000 dementia cases in the UK

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links